Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

competition on the Company's generic products, decreased net sales of Megace(R) ES, and lower royalty income.

Revenues for the generic products division during the three month period decreased 36.4% to $92.9 million compared with the same period in 2007 due to competitive pressure, including for fluticasone, ranitidine HCl syrup, cabergoline, and a decline in many of the Company's other products due to pricing pressures as well as lower royalties driven from ondansetron ODT. Partially offsetting the decreases were increased sales of metoprolol resulting from the launch of additional strengths in the third quarter of 2007 and various amoxicillin products. Second quarter 2008 revenue for Strativa decreased to $20.0 million from $21.6 million in the prior year due to decreased net sales of Megace(R) ES.

Par's second quarter gross margin was 22.2% of sales, compared with 33.7% in 2007. This decrease is primarily attributed to increased sales of lower margin metoprolol, lower royalty income, lower sales of higher margin products such as propranolol, and a decline in many of the Company's other generic products due to pricing pressures, tempered by higher relative sales of Megace(R) ES. The gross margin rate for Strativa was 79.3% in the second quarter of 2008 compared with 72.5% in the same period in 2007.

Research and development (R&D) expense increased $1.7 million or 11.8% to $16.0 million in the second quarter of 2008, driven primarily by an increase in on-going development costs associated with the expansion of Par's generic portfolio and includes Strativa's research costs related to the development of Zensana(TM) and an initial payment related to the in-licensing agreement with MonoSol Rx.

Second quarter selling, general and administrative (SG&A) expense increased 7.9% to $36.7 million compared with the second quarter of 2007. The increase was driven by legal fees related to ongoing litigation, including Paragraph IV litigation costs. Th
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to ... imaging within a body lumen (open space). Known ... low cost, single-use disposable illumination and camera module (housing). ... 2013 and the patent approval was received on January ... customize the lighting and magnification of the endoscope for ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/20/2015)... 20, 2015 Research and Markets ( ... "Top Technologies in HW_Technical Insights" report to their ... evaluated technology trends in the Health and Wellness sector ... to have an impact in the year 2015. The ... top 10 health and wellness technologies that are anticipated ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... by the burgeoning demand from drug discovery research and high throughput ... to amount to $5.0 billion by 2015. A key driving force ... thousands of compounds. , ... San Jose, CA (PRWEB) ...
... FRANCISCO, Calif., Oct. 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... team will host a conference call with,simultaneous webcast to ... a.m. PST/8:30 a.m. EST., Conference Call and Webcast ... 800-265-0241 (domestic) or,617-847-8704 (international) 10 minutes prior to the ...
... Options for Patients with Aortic ... ... announced,today that its Division of Vascular Surgery was the first to ... the treatment of abdominal aortic aneurysms (AAA). The procedure was,performed at ...
Cached Biology Technology:Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3Rigel to Host Update Conference Call 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... Hopkins scientists have discovered that a particular protein helps ... mammalian development. Their results shed light on the subset ... gene that holds the code for the protein, called ... failings of the degenerative diseases are related. As ...
... mixed waste from the paper industry with ceramic material used ... has low thermal conductivity meaning it acts as a good ... "The use of paper industry waste could bring about economic ... waste can be reused as raw material." This is ...
... December 2012, 30 research institutions from 15 European countries, ... associated partners started EU BON - "Building the European ... aims to advance biodiversity knowledge by building a European ... range of biodiversity data both from on ground ...
Cached Biology News:Protein creates paths for growing nerve cells 2Paper waste used to make bricks 2Bringing big data to biodiversity 2Bringing big data to biodiversity 3
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
Homo sapiens jumping translocation breakpoint...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
Biology Products: